Chinook Therapeutics, Inc.
97 articles with Chinook Therapeutics, Inc.
-
Chinook Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
3/7/2023
Chinook Therapeutics, Inc. today announced that Chinook management is scheduled to participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 3:20 pm ET, as well as 1x1 meetings.
-
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - March 03, 2023
3/3/2023
Chinook Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved new employment inducement grants of stock options to purchase a total of 202,290 shares of common stock and restricted stock units for 61,145 shares with a grant date of January 31, 2023 for nine new employees.
-
Chinook Therapeutics Announces Upcoming Presentations at the 5th Chronic Kidney Disease Drug Development Summit
2/28/2023
Chinook Therapeutics, Inc. today announced upcoming presentations at the 5th Chronic Kidney Disease Drug Development (CKD) Summit in Boston, MA from March 7 – 9, 2023.
-
Chinook Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
2/27/2023
Chinook Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022 and provided corporate updates.
-
Chinook Therapeutics Announces the Appointment of Andrew Oxtoby as Chief Commercial Officer
2/15/2023
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Andrew Oxtoby as chief commercial officer.
-
Chinook Therapeutics to Present at SVB Securities Global Biopharma Conference
2/7/2023
Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced that Chinook management is scheduled to participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 11:20 am ET, as well as 1x1 meetings.
-
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 06, 2023
2/6/2023
Chinook Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved new employment inducement grants of stock options to purchase a total of 28,957 shares of common stock and restricted stock units for 14,478 shares with a grant date of January 31, 2023 for five new employees pursuant to the Company’s 2022 Equity Inducement Plan.
-
Chinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Chinook Therapeutics, Inc. announced that Chinook management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2023 at 11:15 am EST, and participate in 1x1 meetings.
-
Chinook Therapeutics to Present at Upcoming Investor Conferences - November 22, 2022
11/22/2022
Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in fireside chats and one-on-one meetings at the following upcoming investor conferences:
-
Therapeutics to halt the progression of chronic kidney disease are in Phase III trials, and others will enter that stage soon. NDAs could follow as early as 2024 with regulatory determinations in 2025.
-
Chinook Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
11/10/2022
Chinook Therapeutics, Inc. provided a business update and reported financial results for the quarter and nine months ended September 30, 2022.
-
Biopharma's efforts to conquer immunoglobulin A nephropathy were on full display at ASN's Kidney Week as Ionis, Chinook and Vera all reported positive data.
-
Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and CHK-336 Preclinical Efficacy Data at the American Society of Nephrology (ASN) Kidney Week 2022
11/4/2022
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced two posters on the BION-1301 and CHK-336 programs being presented today at ASN Kidney Week 2022 being held virtually and live in Orlando, Florida.
-
Chinook Therapeutics Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022
11/3/2022
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced two posters and three informational posters being presented today at ASN Kidney Week 2022 being held virtually and live in Orlando, Florida.
-
Chinook Therapeutics to Present at Upcoming November 2022 Investor Conferences
11/2/2022
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in the following upcoming investor conferences.
-
Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the American Society of Nephrology (ASN) Kidney Week 2022
10/14/2022
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced nine abstracts to be presented at ASN Kidney Week 2022 from November 3 – 6, 2022 in Orlando, Florida.
-
Chinook Therapeutics to Present at Upcoming September 2022 Investor Conferences
9/1/2022
Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in fireside chats and one-on-one meetings at the following upcoming investor conferences.
-
Chinook Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
8/8/2022
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, provided a business update and reported financial results for the quarter and six months ended June 30, 2022.
-
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Aug 04, 2022
8/4/2022
Chinook Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved a new employment inducement grant of stock options to purchase a total of 24,700 shares of common stock with a grant date of July 29, 2022 for one new employee.
-
Chinook Therapeutics to Present at Upcoming Investor Conferences - Aug 02, 2022
8/2/2022
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in the following upcoming investor conferences.